Amisulpride for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Tropisetron.
- Who it may be relevant to
- Registry conditions: PONV. Basic parameters: 18 years — 75 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Amisulpride Used for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery: a Prospective Observational Cohort Study
Overview
This study aims to focus on patients undergoing gynecological laparoscopic surgery and further evaluate the role of amisulpride in preventing postoperative nausea and vomiting in these patients.
Detailed description
Gynecological laparoscopic surgery patients usually combine multiple high-risk factors such as being 'female,' undergoing 'laparoscopic procedures,' and having 'gynecological surgery,' making the prevention and treatment of PONV a key focus and challenge.Among patients undergoing gynecological laparoscopic surgery, there is still a lack of targeted clinical data support.
Interventions
- Drug Tropisetron
and receive tropisetron (2mg) as a postoperative prophylactic antiemetic
Primary outcome measures
- Complete remission (CR) rate within 24 hours postoperatively [Time frame: 1 day]
Eligibility criteria
Inclusion criteria
- 1\. 18<BMI≤30kg/m2 2. Patients scheduled to undergo gynecological laparoscopic surgery (e.g., ovary, fallopian tube, uterus, and gynecological tumors, etc., with an expected surgery duration of ≤3 hours)
Exclusion criteria
- 1\. ASA class IV or above 2. Long-term use of opioid drugs or non-steroidal anti-inflammatory drugs 3. Undergoing radiotherapy and chemotherapy 4.Allergic to the medication used 5.Pregnant or breastfeeding women 6.Previously existing vestibular disorders or chronic dizziness, easily nauseous 7.Recent use of antiemetic drugs or prophylactic antiemetic regimen (within 7 days before surgery) 8.Presence of neurological or psychiatric disorders, or cognitive impairment
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07554040 · 20260539